secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vaxcyte, Inc. (PCVX)
CIK:        0001649094
Form:       8-K
Filed at:   2026-05-06T23:59:59+00:00
Accession:  0001649094-26-000015
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vaxcyte Q1 net loss $320.6M; OPUS Phase 3 enrollment completed; topline data Q4 2026
--------------------------------------------------------------------------------

- Cash $2.74B as of Mar 31, up from $2.44B Dec 31; includes $601.8M from Feb 2026 equity offering.
- Net loss $320.6M for Q1 2026 vs $140.7M in Q1 2025; R&D expenses doubled to $312.8M.
- All three VAX-31 adult Phase 3 trials (OPUS-1, OPUS-2, OPUS-3) fully enrolled with 6,191 adults dosed.
- Topline OPUS-1 data expected Q4 2026; OPUS-2 and OPUS-3 data expected H1 2027.
- VAX-31 infant Phase 2 fully enrolled (900 infants); topline data by end of H1 2027; VAX-A1 Phase 1 start mid-2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649094/000164909426000015/0001649094-26-000015-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649094/000164909426000015/pcvx-20260506.htm
  HTML page:      https://secwatch.observer/filing/0001649094-26-000015

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer